Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2006-05-02
2006-05-02
Nazario-Gonzalez, Porfirio (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C514S492000
Reexamination Certificate
active
07038071
ABSTRACT:
Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
REFERENCES:
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 5117022 (1992-05-01), Khokhar et al.
patent: 5648384 (1997-07-01), Kidani et al.
patent: 5922689 (1999-07-01), Shaw
patent: 6001817 (1999-12-01), Shaw
patent: 6011166 (2000-01-01), Valsecchi et al.
patent: 6130245 (2000-10-01), Shaw
patent: 6194403 (2001-02-01), Hu et al.
patent: 6297245 (2001-10-01), Shaw
patent: 6331559 (2001-12-01), Bingham et al.
patent: WO 00/63219 (2000-10-01), None
Leonetti, C., et al., “α-Tocherol Protects Against Cisplatin-Induced Toxicity Without Interfering With Antitumor Efficacy,”Int. J. Cancer 104(2):243,250, 2003.
Manzotti, C., et al., “BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin,”Clinical Cancer Res. 6:2626-2634, Jul. 2000.
Martin-Ramos, J.D., et al., “Copper(II) and Nickel(II) Chelated With Dihydrogen Trans-1,2-Diaminocyclohexane-N,N,N'N'-Tetraacetate(2-) Ion (H2CDTA2-). Synthesis, XRD Structure and Properties of [Cu(H2CDTA)] H2O and [Ni(H2CDTA)(H2O)] 4H2O)”,Polyhedron 15(3)439-446, 1996.
Pace, A., et al., “Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy,”J. Clin. Oncol. 21(5):927-391 Mar. 2003.
Akerley, W., et al., “Weekly, High-Dose Paclitaxel in Advanced Lung Carcinoma,”Cancer 97(10):2480-2486, May 15, 2003.
Baumgartner, M.R. et al. “The Interaction of Transition Metals With the Coenzyme α-Lipoic Acid: Synthesis, Structure and Characterization of Copper and Zinc Complexes,”Inorganica Chimica Acta 252:319-331, Nov. 1996.
Farrell, N., “Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents,” in L.R. Kelland and N. Farrell (eds.),Platinum-Based Drugs in Cancer Therapy,Humana Press Inc., Totowa, New Jersey, Jun. 2000, pp. 321-339.
Fuertes, M.A., et al., “Novel Concepts in the Development of Platinum Antitumor Drugs,”Curr. Med. Chem.—Anti-Cancer Agents 2(4):539-551, 2002.
Hegmans A., et al., “Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum-Spermidine Species Through Hydrolytic Cleavage of Carbamates,”Inorg. Chem. 40(24):6108-6114, Oct. 20, 2001.
Qu, Y., et al., “Synthesis, Characterization, and Cytotoxicity of Trifunctional Dinuclear Platinum Complexes: Comparison of Effects of Geometry and Polyfunctionality on Biological Activity,”J. Med. Chem. 43(16):3189-3192, Jul. 20, 2000.
Serimaa, R., et al., “X-Ray Scattering Study on Amorphous, Polynuclear Platinum Uridine Complexes,”J. Am. Chem. Soc 115(22):10036-10041, Nov. 3, 1993.
Christensen O'Connor Johnson & Kindness PLLC
Nazario-Gonzalez Porfirio
Sonus Pharmaceuticals Inc.
LandOfFree
Platinum compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platinum compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3644114